{"id":"eylea-hd-aflibercept-hd","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular pressure elevation"},{"rate":null,"effect":"Endophthalmitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for VEGF-A and PlGF, preventing these growth factors from binding to their endogenous receptors on vascular endothelial cells. By sequestering VEGF, it reduces pathological neovascularization and vascular permeability in retinal diseases. The HD (high-dose) formulation allows for less frequent dosing while maintaining therapeutic efficacy.","oneSentence":"Eylea HD is a high-dose formulation of aflibercept, a VEGF trap that binds and inhibits vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:15.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion"},{"name":"Myopic choroidal neovascularization"}]},"trialDetails":[{"nctId":"NCT07489131","phase":"PHASE3","title":"Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema","status":"NOT_YET_RECRUITING","sponsor":"Alvotech Swiss AG","startDate":"2026-03","conditions":"Diabetic Macular Edema","enrollment":256},{"nctId":"NCT07118670","phase":"PHASE4","title":"High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edward Wood, MD","startDate":"2025-12-08","conditions":"Proliferative Diabetic Retinopathy (PDR)","enrollment":40},{"nctId":"NCT03845049","phase":"PHASE3","title":"Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2019-07-03","conditions":"Macular Telangiectasia","enrollment":16},{"nctId":"NCT06422507","phase":"PHASE3","title":"A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-05-29","conditions":"Diabetic Macular Edema","enrollment":333},{"nctId":"NCT06591598","phase":"PHASE4","title":"A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-09-02","conditions":"Diabetic Macular Edema, Neovascular Age-related Macular Degeneration","enrollment":51},{"nctId":"NCT06491914","phase":"PHASE3","title":"A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-07-24","conditions":"Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema","enrollment":1118},{"nctId":"NCT04423718","phase":"PHASE3","title":"Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-08-11","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1011},{"nctId":"NCT07129239","phase":"PHASE3","title":"High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)","status":"NOT_YET_RECRUITING","sponsor":"Clinique de Retine de l'est","startDate":"2025-08-20","conditions":"Wet Age-related Macular Degeneration (wAMD)","enrollment":180},{"nctId":"NCT05989126","phase":"PHASE3","title":"Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-04-15","conditions":"Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":35},{"nctId":"NCT06398080","phase":"","title":"An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting","status":"WITHDRAWN","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-12-12","conditions":"Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME)","enrollment":""},{"nctId":"NCT04126317","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-11-04","conditions":"Neovascular (Wet) Age-Related Macular Degeneration","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Eylea HD (aflibercept HD)","genericName":"Eylea HD (aflibercept HD)","companyName":"Alvotech Swiss AG","companyId":"alvotech-swiss-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eylea HD is a high-dose formulation of aflibercept, a VEGF trap that binds and inhibits vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye. Used for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}